Clinical trial
Rituximab Followed by Combination Chemotherapy in Treating Patients With…
NCT00006669 · Medstar Health Research Institute, Other · Withdrawn
Key facts
| NCT number | NCT00006669 |
|---|---|
| Title | Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma |
| Official title | Phase II Trial of EPOCH and Rituxan Combined Therapy in Patients With Refractory or Relapsed CD20 Positive Intermediate Grade B-cell Non-Hodgkin's Lymphoma |
| Lead sponsor | Medstar Health Research Institute, Other |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | rituximab, sargramostim, EPOCH regimen, cyclophosphamide, doxorubicin hydrochloride, etoposide, prednisone, vincristine sulfate |
| Enrollment | 0 |
| Start date | Sep 1, 1999 |
| Primary completion | Jan 1, 2000 |
| Completion | Jan 1, 2000 |
| First posted | May 4, 2004 |
| Last update posted | Oct 27, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: